Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arrowhead Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was MXN3,636 Mil.
Arrowhead Pharmaceuticals's quarterly Beginning Cash Position
increased
from Sep. 2025 (MXN2,381 Mil) to Dec. 2025 (MXN4,079 Mil) but then
declined
from Dec. 2025 (MXN4,079 Mil) to Mar. 2026 (MXN3,636 Mil).
Arrowhead Pharmaceuticals's annual Beginning Cash Position
increased
from Sep. 2023 (MXN1,881 Mil) to Sep. 2024 (MXN2,183 Mil) but then
declined
from Sep. 2024 (MXN2,183 Mil) to Sep. 2025 (MXN1,884 Mil).
Arrowhead Pharmaceuticals Beginning Cash Position Related Terms
Arrowhead Pharmaceuticals Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Arrowhead Pharmaceuticals's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals Beginning Cash Position Chart
What does a Beginning Cash Position of MXN3,636 Mil mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Beginning Cash Position of MXN3,636 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Beginning Cash Position too high?
Arrowhead Pharmaceuticals' current Beginning Cash Position is MXN3,636 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Beginning Cash Position compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Beginning Cash Position of MXN3,636 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Beginning Cash Position is MXN3,636 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Beginning Cash Position of MXN3,636 Mil. The stock's GF Value™ is MXN304.90, compared to a current price of MXN454.55 — trading 49.1% above its estimated fair value. The current Beginning Cash Position is MXN3,636 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Beginning Cash Position is MXN3,636 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN454.55 is trading 49.1% above its estimated GF Value™ of MXN304.90.
Key valuation signals for MEX:ARWR:
Beginning Cash Position: MXN3,636 Mil
GF Value™: MXN304.90 vs. price of MXN454.55 (49.1% above fair value)
No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
45GF Score
Get the complete analysis for MEX:ARWR
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARWR has been successfully added to your 
